/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a wide range of serious medical conditions. With a strong portfolio of therapies addressing diseases such as eye disorders, allergic and inflammatory conditions, infectious diseases, cancer, and cardiovascular issues, it leverages cutting-edge science to improve patient outcomes. The Tarrytown, New York-based company is expected to unveil its fiscal Q4 earnings results before the market opens on Tuesday, Feb. 4.
Ahead of the event, analysts forecast the biopharmaceutical company to post a profit of $9.57 per share, reflecting a decrease of nearly 6% from $10.18 per share in the same quarter last year. The company has exceeded Wall Street's bottom-line projections in three of the past four quarters while missing on another occasion. REGN surpassed the consensus EPS estimate by a margin of 16.6% in the last reported quarter.